Grünenthal receives Brazilian ANVISA certification for Tecnandina production plant in Ecuador
Family-owned German drugmaker Grünenthal Group says that its Tecnandina manufacturing plant in Ecuador has received certification from the Regulatory Authority of Brazil, ANVISA. This will allow Tecnandina to export pharmaceutical products also to Brazil and makes it the first production plant in Ecuador to receive ANVISA certification.
“We are very pleased that our plant in Ecuador can now also be a full service supply partner for Brazil as it is already for Andean countries and the Mexican market. The ANVISA certification is another key milestone in demonstrating our high quality capabilities in global contract manufacturing,” states Alberto Grua, a member of the corporate executive board of Grünenthal.
The Grünenthal Group offers contract manufacturing from its five independent production plants throughout Europe and Latin America.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze